Abstract Number: 0588 • ACR Convergence 2025
The effect of biological and targeted synthetic DMARDs on peripheral manifestations in axial spondyloarthritis: a systematic literature review
Background/Purpose: In axial spondyloarthritis (axSpA), peripheral musculoskeletal manifestations (peripheral arthritis, enthesitis, dactylitis) are common and contribute to the burden of disease. Our objective was to…Abstract Number: 0541 • ACR Convergence 2025
Inflammatory Back Pain Is Not Associated With HLA-B27 Positivity or CRP Levels in a Nationally Representative U.S. Population
Background/Purpose: Inflammatory back pain (IBP) is a hallmark symptom of axial spondyloarthritis (axSpA) and is frequently used as a clinical entry point for further evaluation,…Abstract Number: 0390 • ACR Convergence 2025
Radiographic Assessment in Juvenile Spondyloarthritis: Evaluating the axJSpA Criteria Using Radiographs Alone Versus MRI
Background/Purpose: Radiographs are neither sensitive nor reliable for assessing axial disease in juvenile spondyloarthritis (JSpA), though they are still used in some settings due to…Abstract Number: 2352 • ACR Convergence 2025
Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update
Background/Purpose: Uveitis is a common extra-musculoskeletal manifestation in patients (pts) with spondyloarthritis (SpA); incidence varies with SpA type and disease duration.1–3 IL-17 has been implicated…Abstract Number: 2310 • ACR Convergence 2025
Neuropeptide influence in nociception and inflammation through immune system modulation in SPA patients
Background/Purpose: NGFβ and CGRP are neuropeptides with a significant role in peripheral inflammation, pain modulation and immune responses. Neuropeptides regulatory mechanisms in spondyloarthritis (SpA) remain…Abstract Number: 1753 • ACR Convergence 2025
Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model
Background/Purpose: Psoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disorder involving the axial skeleton in approximately 30% of patients. The mechanisms that underlie psoriatic…Abstract Number: 1423 • ACR Convergence 2025
Genetic and Cytokine Correlates in Ankylosing Spondylitis: rs27038 polymorphism of ERAP1 gene and IL-17 Interactions : A Case-Control Study
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disorder primarily affecting the axial skeleton and associated with HLA-B27. Non-HLA genes, including ERAP1 (Endoplasmic Reticulum Aminopeptidase…Abstract Number: 0578 • ACR Convergence 2025
Real-world Effectiveness of Upadacitinib on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Core Domains for Patients with Psoriatic Arthritis: Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous inflammatory disease that can cause substantial impairment in quality of life in affected patients. The Group for Research…Abstract Number: 0540 • ACR Convergence 2025
Low-Dose CT reveals syndesmophyte progression in axial SpA, particularly in the thoracic spine: Insights from the SPACE cohort covering early and established disease
Background/Purpose: Low-dose computed tomography (ldCT) has not previously been used to assess pt with axial spondyloarthritis (axSpA) early in their disease course, especially those with…Abstract Number: 0386 • ACR Convergence 2025
Introducing the Multidimensional Pain Inventory as a Comprehensive Tool or Assessing Pain in Patients With Axial Spondyloarthritis
Background/Purpose: The West Haven-Yale Multidimensional Pain Inventory (MPI) is a validated tool designed to assess the multidimensional aspects of chronic pain, including the 5 dimensions…Abstract Number: 2349 • ACR Convergence 2025
Classification of “Difficult-to-Manage Axial Spondyloarthritis”: A Real-World Cohort Study Evaluating the ASAS 2024 Criteria Over Time
Background/Purpose: The concept of difficult-to-manage axial spondyloarthritis (D2M-axSpA)[1], may vary over time. Transitions between D2M and non-D2M classifications throughout the disease course remain unclear. This…Abstract Number: 2308 • ACR Convergence 2025
Physical Function Mediates Most—but Not All—of the Effect of Disease Activity on Health-Related Quality of Life in Axial Spondyloarthritis: A 10-Year Longitudinal Analysis
Background/Purpose: Health-related quality of life (HRQoL) is an overarching outcome in axial spondyloarthritis (axSpA), and is considered influenced by disease activity and physical function. However,…Abstract Number: 1466 • ACR Convergence 2025
Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
Background/Purpose: Spinal inflammation and structural progression are key features of radiographic axial spondyloarthritis (r-axSpA).1 Canada-Denmark (CANDEN) scoring enables anatomical-based assessments of MRI inflammatory and structural…Abstract Number: 1420 • ACR Convergence 2025
A Nationwide Analysis of In-Hospital Mortality in Adult Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease with systemic complications that may contribute to increased mortality risk. This study examines the characteristics and…Abstract Number: 0575 • ACR Convergence 2025
Why Do Some Psoriatic Arthritis Patients Fail Treatment? Exploring the Profile of D2T Patients
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease combining psoriasis (Pso) and arthritis. Despite the availability of multiple therapeutic options, many patients experience residual…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 49
- Next Page »
